A Prospective Observational Study Conducted in France to Describe Routine Clinical Practice for Treatment naïve or Previously Treated Patients With Diabetic Macular Edema (DME) Who Are Starting IVT Aflibercept
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms APOLLON
- Sponsors Bayer
- 30 Mar 2018 Planned primary completion date changed from 15 Sep 2019 to 15 Jul 2019.
- 03 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Oct 2016 New trial record